Viatris JANZ — Finite-lived intangible assets, net decreased by 9.4% to $946.20M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 9.4%, from $1.04B to $946.20M.
A declining balance suggests aging product portfolios or high amortization rates, while a stable balance indicates ongoing investment in new intellectual property.
The net book value of identifiable intangible assets, such as patents, trademarks, and customer relationships, that have...
Standard balance sheet item for pharma companies; peers report as 'Net Intangible Assets' by segment.
vtrs_segment_janz_finite_lived_intangible_assets_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.50B | $1.33B | $1.18B | $1.04B | $946.20M |
| QoQ Change | — | -11.4% | -11.2% | -11.3% | -9.4% |
| YoY Change | — | -11.4% | -11.2% | -11.3% | -9.4% |